Jaypirca is a non covalent inhibitor targeting BTK, primarily used to treat specific types of B-cell malignancies, including relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma treated with multi line therapy.

1. Recurrent or refractory mantle cell lymphoma (MCL)

(1) Target audience: Adult patients who have received at least two systemic treatments in the past (including BTK inhibitors).

(2) Clinical value: It still shows efficacy in BTK inhibitor resistant patients and provides a new option for relapsed and difficult to treat cases.

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

(1) Applicable conditions: Adult patients must have received at least two types of systemic therapy in the past (including BTK inhibitors and BCL-2 inhibitors).

(2) Therapeutic advantage: As a posterior therapy, it can overcome the problem of resistance to traditional BTK inhibitors.